StemCell Therapy

Global Rheumatoid Arthritis Treatment Market Research Report offers a in-depth view on market trends, forecast statistics, company profile, growth drivers and latest industry insights. The report covers all the Rheumatoid Arthritis Treatment type, applications, deployment models, research regions. A deep-dive analysis on leading Rheumatoid Arthritis Treatment industry players, their market share, production volume, gross margin analysis from 2015-2019 is provided. Challenges to the Rheumatoid Arthritis Treatment development, growth opportunities, market drivers, restraints are described in this report.

The market value, market share, production and gross margin of Rheumatoid Arthritis Treatment is covered for every type, application, and geographical regions. Also, import-export scenario, regional SWOT analysis, and market status is elaborated. Rheumatoid Arthritis Treatment Forecast covers type, application and regional forecast for market value, volume, and consumption from 2020 to 2026. Industry barriers, investment feasibility, and opportunities to the new Rheumatoid Arthritis Treatment market players are analyzed in this report.

Global Rheumatoid Arthritis Treatment market is subdivided based on type, application and research regions. Top regions studied in this report include North America, Europe, Asia-Pacific, South America, Middle East & Africa. For each region, production value and growth rate is covered from 2015 to 2019. The information on market concentration and market maturity analysis will lead to investment feasibility.

Get Free Sample(COVID-19 Impact Analysis Updated Sample):@:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#request_sample

Major players covered in this report:

Johnson & JohnsonAmgen Inc.Sobi Inc.UCB S.A.Eli Lilly & CompanySanofi SAAbbVie Inc.Pfizer Inc.Bristol-Myers Squibb CompanyF. Hoffman-La Roche AG

Global Rheumatoid Arthritis Treatment Market Segmentation:

By Type:

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)CorticosteroidsDisease-modifying anti-rheumatic drugs (DMARDs)

By Application:

HospitalRetail PharmaciesDrugstores

Market drivers explain the emerging countries and Rheumatoid Arthritis Treatment growth. Also, the limitations, opportunities, latest industry plans, and policies are offered. Industry chain analysis explains upstream raw material suppliers, key market players, production process analysis, Rheumatoid Arthritis Treatment manufacturing cost structures, and global market share of Rheumatoid Arthritis Treatment in 2019. This in-depth study explains the cost of raw materials, labor cost, marketing channels and major downstream buyers of Rheumatoid Arthritis Treatment.

Get Up to 30% Off on purchasing this report, Ask Here for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/146290

This study analyzes the Rheumatoid Arthritis Treatment industry market status and forecast statistics explaining the production, revenue, consumption ratio, and historic market trends. All the manufacturers, market share, company profiles, production capacity, and gross margin analysis of Rheumatoid Arthritis Treatment is presented in this report. The industry breakdown based on product type, applications, regions, and manufacturer will provide sophisticated Rheumatoid Arthritis Treatment market view. Recent Rheumatoid Arthritis Treatment developments, opportunities, challenges, and business strategies are explained. The influencing factors, product launches, mergers and acquisition of Rheumatoid Arthritis Treatment is covered in this study.

The report also explains the demand and supply side of Rheumatoid Arthritis Treatment, revenue estimates, competitive scenario, and sales data. Rheumatoid Arthritis Treatment value chain, market status, and price trends are explained in detail. Rheumatoid Arthritis Treatment industry presence across different geographies covers the regions like North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Further, the countries like United States, Canada, Mexico, China, Japan, Korea, India, Australia, Indonesia, Singapore, Germany, United Kingdom, France, Italy, Spain, Russia, Brazil, Argentina, UAE, Saudi Arabia, Turkey and the rest are analyzed in this report.

Enquire For Complete Sample Report Copy Or Request For Customization:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#inquiry_before_buying

Reasons To Buy This Report:

Rheumatoid Arthritis Treatment Report Effectively Addresses The Below Queries.

Explore Detailed Table Of Content With Table Of Figures: @

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#table_of_contents

Visit link:
Global Rheumatoid Arthritis Treatment Market Expected To Witness The Highest Growth 2027 | Johnson & Johnson, Amgen Inc., Sobi Inc., UCB SA, Eli...

Non-contact, high-resolution imaging for uveitis surveillance in juvenile idiopathic arthritis (JIA) is feasible and acceptable to patients with the disease, according to study results published in Arthritis & Rheumatology.

Disease activity in anterior uveitis is traditionally assessed using slit lamp biomicroscopy; however, this modality is semiquantitative and image interpretation is subjective. Optical coherence tomography (OCT) may represent a better metric of measuring inflammatory disease, with recent modifications to OCT allowing the imaging of the anterior chamber.

In the current study, researchers sought to assess the feasibility and accuracy of cross-sectional anterior segment OCT (AS-OCT) for the diagnosis of active uveitis in JIA.

In the cross-sectional observational study, the researchers enrolled children with and without uveitis from a specialist pediatric uveitis center in England between 2017 and 2018. The 2 groups of participants included children with JIA and a diagnosis of chronic anterior uveitis; and children without both JIA and uveitis. All children received routine clinical assessment of the anterior chamber with a slit lamp. The ordinal Standardized Uveitis Nomenclature (SUN) anterior chamber activity cell count grade was used to diagnose inflammation.

The AS-OCT scans of the anterior chamber were then acquired. Patients were asked to focus their eye that was being tested on the machine fixation beam. Image acquisition time was measured, and participants were asked to rate the acceptability of the acquisition process. The AS-OCT images were analyzed manually for the presence of anterior chamber inflammation. Examiners were blinded to the results of the initial clinical examination. Correlation between imaging-acquired cell count and clinical assessment was calculated using a multilevel linear regression model. Sensitivity, specificity, and repeatability were also reported.

A total of 26 children received AS-OCT imaging, among whom 18 (69.2%) were girls. Median age was 8 years (age range, 3-15 years). Twelve children had active anterior inflammation during their initial clinical examination. Time taken to acquire AS-OCT images from both eyes ranged from 1.5 to 22 minutes, with a median value of 8 minutes. Patients rated image acquisition acceptability as high, with a median visual analog scale score of 9.5 of a possible 10.

Intraobserver image agreement was high with regard to manual cell count (intraclass observer coefficient, 0.81; 95% CI, 0.63-0.98). There was moderate agreement on cell count between observers (kappa statistic [], 0.46; 95% CI, 0.28-0.63), and between-observer disagreement on the presence of intraocular cells in 25 of the 377 reviewed images (6.6%). Anterior segment OCT had high correlation with active inflammation as diagnosed by slit lamp examination. Sensitivity for active inflammation was 91.7% (95% CI, 61.5%-99.8%); specificity was 85.7% (95% CI, 57.2%-89.2%); and accuracy was 88.5% (95% CI, 69.9%-97.6%). In multilevel regression modeling, there was high positive correlation between clinical assessment and image-based cell count (coefficient, 3.3; 95% CI, 1.3-5.2; P =.002). No children without uveitis had a positive result on AS-OCT imaging.

These results support the feasibility and acceptability of AS-OCT imaging for the assessment of uveitis in children with JIA.

The primary study limitation was the small sample size and the fact that the study results may not be generalizable to all children with anterior chamber inflammation. While AS-OCT correlated well with slit lamp examination, further study is necessary to standardize the imaging protocol.

Imaging-based metrics for uveitis holds the promise of providing sensitive, robust, validated measurement of disease status which, alongside [standardized] datasets and patient[-centered] metrics, can also improve service provision, prognostication and precision in disease management for affected or at-risk children, the researchers concluded.

Akbarali S, Rahi JS, Dick AD, et al. Imaging based uveitis surveillance in juvenile idiopathic arthritis: feasibility, acceptability and diagnostic performance. Arthritis Rheumatol. Published online September 25, 2020. doi:10.1002/art.41530

View original post here:
Imaging-Based Uveitis Surveillance Feasible for Patients With Juvenile Idiopathic Arthritis - Rheumatology Advisor

Objective:To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).

Methods:Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (NCT02029495andNCT02024646) and randomised 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks. About 30% of patients had prior use of biologics. The primary endpoint for both studies was the American College of Rheumatology 20 (ACR20) response at week 16.

Results:962 patients were randomised across the studies prior to early termination due to sponsor decision. The primary endpoint was met in both studies. Based on comparable design and eligibility criteria, data from both studies were pooled. Significantly more patients achieved ACR20 at week 16 in both brodalumab treatment groups (45.8% and 47.9% for 140 mg and 210 mg, respectively) versus placebo (20.9%) (p<0.0001). Similar results were observed at week 24. Significantly higher proportions of patients receiving brodalumab achieved ACR50/70, Psoriasis Area and Severity Index 75/90/100 and resolution of dactylitis and enthesitis versus placebo (p<0.01). Adverse event rates were similar across treatments at week 16 (54.4%, 51.6% and 54.5% for placebo, brodalumab 140 mg and 210 mg, respectively). No new safety signals were reported.

Conclusion:Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.

Keywords:DMARDs (biologic); autoimmune diseases; psoriatic arthritis.

Go here to read the rest:
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials - DocWire News

- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis

- Presentations to highlight patient-reported outcomes of RINVOQ in people living with psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis

- New safety and efficacy data of RINVOQ through 64 weeks in treating ankylosing spondylitis, as well as an integrated safety analysis for psoriatic arthritis, will also be presented

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ (upadacitinib) and HUMIRA (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

"At AbbVie, we have a focused vision of improving the care and advancing treatment options for people living with rheumatic diseases, which is illustrated by the body of research that will be presented at this year's ACR meeting," said Marek Honczarenko M.D., Ph.D., vice president, global immunology development, AbbVie. "These data underscore the potential for RINVOQ and HUMIRA to help more people living with rheumatic diseases reach their goals."

Data evaluating the long-term safety and efficacy of RINVOQ in rheumatoid arthritis will be presented, including:

84-week data on RINVOQ as a monotherapy in patients with inadequate response to methotrexate

72-week RINVOQ monotherapy data in methotrexate-nave patients

72-week data comparing RINVOQ versus HUMIRA in patients with inadequate response to methotrexate

An integrated safety update reflecting up to three years of treatment with RINVOQ

Oral presentations will also highlight the safety and efficacy of RINVOQ in the treatment of psoriatic arthritis (through 24 weeks) and ankylosing spondylitis (through 64 weeks), while a poster presentation will provide a new integrated safety analysis from two Phase 3 trials evaluating the safety profile of RINVOQ in psoriatic arthritis.

Story continues

Further, several presentations will show patient-reported outcomes for RINVOQ in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including its impact on pain reduction and physical function.

Key AbbVie rheumatology abstracts in the ACR Convergence 2020 program include:

Rheumatoid Arthritis

Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis. SB Cohen, et al. Abstract Number: 0237; Poster Session: Friday, November 6, 9 11 a.m. EST

Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks. R Fleischmann, et al. Abstract Number: 0212; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks. JS Smolen, et al. Abstract Number: 0209; Poster Session: Friday, November 6, 9 11 a.m. EST

Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program. E Choy, et al. Abstract Number: 0215; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib Monotherapy in Methotrexate-nave Patients with Rheumatoid Arthritis: Results at 72 Weeks. R van Vollenhoven, et al. Abstract Number: 0207; Poster Session: Friday, November 6, 9 11 a.m. EST

Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study. E Mysler, et al. Abstract Number: 0228; Poster Session: Friday, November 6, 9 11 a.m. EST

Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years. CG Peterfy, et al. Abstract Number: 1231; Poster Session: Sunday, November 8, 9 11 a.m. EST

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study. M Bergman, et al. Abstract Number: 1728; Poster Session: Monday, November 9, 9 11 a.m. EST

Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study. K Winthrop, et al. Abstract Number: 1996; Oral Presentation: Monday, November 9, 10 10:50 a.m. EST

Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib. K Winthrop, et al. Abstract Number: 2002; Oral Presentation: Monday, November 9, 3 3:50 p.m. EST

Psoriatic Arthritis

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. MC Genovese, et al. Abstract Number: 0504; Oral Presentation: Friday, November 6, 3 3:50 p.m. EST

Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs. IB McInnes, et al. Abstract Number: 0896; Poster Session: Saturday, November 7, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study. V Strand, et al. Abstract Number: 1341; Poster Session: Sunday, November 8, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes for Upadacitinib Versus Placebo Among Patients With Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs. V Strand, et al. Abstract Number: 1371; Poster Session: Sunday, November 8, 9 11 a.m. EST

Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis From Two Phase 3 Trials. GR Burmester, et al. Abstract Number: 1350; Poster Session: Sunday, November 8, 9 11 a.m. EST

Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials. P Mease, et al. Abstract Number: 1355; Poster Session: Sunday, November 8, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. IB McInnes, et al. Abstract Number: 2026; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

Ankylosing Spondylitis

Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs. A Deodhar, et al. Abstract Number: 0369; Poster Session: Friday, November 6, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension. A Deodhar, et al. Abstract Number: 2023; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

A full list of all 38 AbbVie abstracts accepted for presentation at ACR Convergence 2020 can be found here.

About RINVOQ (upadacitinib)Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1-3 In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.4-12 Use of RINVOQ in ankylosing spondylitis and psoriatic arthritis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)13

RINVOQ U.S. Use and Important Safety InformationRINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

Serious infections have happened in some people taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your HCP should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You may be at higher risk of developing shingles (herpes zoster).

Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ.

Blood clots in the veins of the legs or lungs and arteries are possible in some people taking RINVOQ. This may be life-threatening and cause death.

Tears in the stomach or intestines and changes in certain laboratory tests can happen. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection such as:

Have TB or have been in close contact with someone with TB.

Have had any type of cancer, hepatitis B or C, shingles (herpes zoster), or blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.

Have other medical conditions including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.

Live, have lived, or have traveled to parts of the country that increase your risk of getting certain kinds of fungal infections, such as the Ohio and Mississippi River valleys and the Southwest. If you are unsure if you've been to these areas, ask your HCP.

Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.

Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose.

Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

Have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.

Have any signs or symptoms of blood clots during treatment with RINVOQ, including:

Have a fever or stomach-area pain that does not go away, and a change in your bowel habits.

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please click here for the Full Prescribing Information and Medication Guide.

About HUMIRA in the U.S.

UsesHUMIRA is a prescription medicine used:

To reduce the signs and symptoms of:

In adults, to help get moderate to severe ulcerative colitis (UC) under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.

To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.

Important Safety InformationHUMIRA is a TNF blocker medicine that affects the immune system and can lower the body's ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy, even if their TB test was negative. People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, as these infections may happen or become more severe if people use HUMIRA. People should tell their doctor if they have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.

For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HUMIRA, the chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated.

Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus; allergic reactions; nervous system problems; blood problems; certain immune reactions, including a lupus-like syndrome; liver problems; and new or worsening heart failure or psoriasis. The use of HUMIRA with anakinra or abatacept is not recommended. People using HUMIRA should not receive live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA.

Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash, and nausea.

HUMIRA is given by injection under the skin.

The benefits and risks of HUMIRA should be carefully considered before starting therapy.

Please click here for the Full Prescribing Information and Medication Guide.

About AbbVie in RheumatologyFor more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

AbbVie Data on File. ABVRRTI70713.

AbbVie Data on File. ABVRRTI70838.

AbbVie Data on File. ABVRRTI70869.

Pipeline Our Science | AbbVie. AbbVie. 2019. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed on August 17, 2020.

Burmester G.R., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02365649. Accessed on August 17, 2020

A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on August 17, 2020.

A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03178487. Accessed on August 17, 2020.

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on August 17, 2020.

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03607422. Accessed on August 17, 2020.

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed on August 17, 2020.

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov. 2020. Available at https://clinicaltrials.gov/ct2/show/record/NCT04161898. Accessed on October 13, 2020.

RINVOQ (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-highlights-innovative-research-for-people-with-rheumatic-diseases-with-new-data-at-acr-convergence-2020-301161316.html

SOURCE AbbVie

See the original post:
AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020 - Yahoo Finance

Fact.MR has recently published a report, titled [Global Rheumatoid Arthritis Stem Cell Therapy Market 2020 by Key Countries, Companies, Type and Application]. The research report provides an in-depth explanation of the various factors that are likely to drive the market. It discusses the future of the market by studying the historical details. Analysts have studied the ever-changing market dynamics to evaluate their impact on the overall market. In addition, the report also discusses the segments present in the market. Primary and secondary research methodologies have been used to provide the readers with an accurate and precise understanding of the overall The Rheumatoid Arthritis Stem Cell Therapy market. Analysts have also given readers an unbiased opinion about the direction companies will take during the forecast period.

The research report also includes the global market figures that provide historical data as well as estimated figures. It gives a clear picture of the growth rate of the market during the forecast period. The report aims to give the readers quantifiable data that is collected from verified data. The report attempts to answer all the difficult questions such as market sizes and company strategies.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Competitive landscape

Global Rheumatoid Arthritis Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers shaping the future of the Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global The Rheumatoid Arthritis Stem Cell Therapy market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global The Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Global Rheumatoid Arthritis Stem Cell Therapy Market: Regional Segmentation

In the successive chapters, analysts have studied the regional segments present in the global The Rheumatoid Arthritis Stem Cell Therapy market. This gives the readers a narrowed-view of the global market enabling a closer look at the elements that could define its progress. It highlights myriad regional aspects such as the impact of culture, environment, and government policies that influence the regional markets.

Global Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

The last chapter of the global The Rheumatoid Arthritis Stem Cell Therapy market research report focuses solely on the competitive landscape. It studies the key players present in the market. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also mentions the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the strategies of the companies and the initiatives they have taken in recent years to overcome the intensive competition.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Read the rest here:
Innovations in the Rheumatoid Arthritis Stem Cell Therapy Field Likely to Aid the Growth of the Rheumatoid Arthritis Stem Cell Therapy Market 2018 to...

Joint pain resulting in arthritis is a common health problem and if you are suffering from arthritis, there are certain foods you need to avoid to prevent from worsening your health conditions. Find out more.

Arthritis is a common health issue that occurs in many adults and younger people. It involves inflammation in your joints that leads to weakening the bones and damaging them. Some people believe that changes in diet are related to increased symptoms in arthritis. This change might be excess of fat and sugar or avoiding foods that are high in purines.

Let us have a look at five types of food that should be avoided if you are suffering from arthritis:

Inflammatory fats

Since inflammatory fats cause inflammation in the body, they are to be avoided by people with arthritis. Foods which include Omega 6 fatty acids like oil, corn, sunflower and vegetable oil. Saturated fat like meat, butter, cheese and trans fat. Trans fat is bad for health anyway as it increases the level of bad cholesterol in the body.

Sugar

People who have processed sugar regularly in their tea or coffee are highly prone to being at risk for having heart strokes. It leads to obesity, inflammation and other chronic diseases. Limit your intake of carbonated drinks, sugar in beverages, cereal bowls and other food items.

Tomatoes, eggplant, potatoes, bell peppers

Removing these food items from your diet or as part of key ingredients in your dishes might help. This improves in reducing the chances of developing any symptoms related to arthritis.

Purines

These are foods that are high in purines, which are substances in foods that the body converts to uric acid. The uric acid can accumulate in blood causing a gout attack. These types of foods include red meat, beer, ham and seafood.

Also Read:What are Shingles and is stress the real cause? Heres all you need to know

x Your comment has been submitted to the moderation queue

Read more from the original source:
THESE are the 5 foods people who suffer from arthritis must avoid - PINKVILLA

The report referring to the Systemic Idiopathic Juvenile Arthritis Treatment market is one of the most widespread and with key impactful additions designed for the buyers. Market Growth Insight has delivered detailed analysis and research on the major aspects of the market including the drivers, restraints, opportunities, challenges, and threats of the market. Complete study on these factors helps the buyers of the report to plan crucial decisions for the upcoming years and gain top rankings among competitors. The Systemic Idiopathic Juvenile Arthritis Treatment market research report is segmented in different key verticals, such as product, application, end user, and geography that are all described with useful information to assist the industry players with their future planning. Also, the report is decorated with the current happenings like ongoing trends, opportunities for the Systemic Idiopathic Juvenile Arthritis Treatment market players, recent news, key developments, and recently adopted strategies. The report also delivers key information like company profiles, import and export, sales, revenues, and more.

North America has a significant international presencein the global Systemic Idiopathic Juvenile Arthritis Treatment market in 2020 accompanied by the Middle East/Africa, Europe, and the Asia Pacific, respectively.

Avail your SAMPLE of the Systemic Idiopathic Juvenile Arthritis Treatment Market Report, here @https://www.marketgrowthinsight.com/sample/16866

Top Leading players operating in the market: Alteogen Inc., Bristol-Myers Squibb Company, Epirus Biopharmaceuticals, Inc., Johnson & Johnson, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oncobiologics, Inc.

Segmentation by Product:

Segmentation by Application:

Growth Dynamics and Geographical Landscape:

The Systemic Idiopathic Juvenile Arthritis Treatment market research report delivers the existing growth changes witness in the industry by the researchers and experts. The report offers thorough analysis on the recent adopted growth strategies by the leading players and offers comprehensive impactful information that helps the new entrants and other existing players to plan their strategies accordingly. The report also provides complete analysis with deep research on the various key geographies that have marked the growth of the Systemic Idiopathic Juvenile Arthritis Treatment market with optimal sales, product demand in the region, distributors, marketing strategies, product pricing, and more. The report covers key insights on the current happenings that will assist the business, companies, investors, and others to understand the scenario of the Systemic Idiopathic Juvenile Arthritis Treatment market, plan activities, and gain prominent positions in the near future.

Report on Systemic Idiopathic Juvenile Arthritis Treatment market will help with the following questions:

1. Which are the leading industry players in the Systemic Idiopathic Juvenile Arthritis Treatment market?2. What is the expected size of the Systemic Idiopathic Juvenile Arthritis Treatment market in the forecast period?3. Which category is anticipated to lead the global Systemic Idiopathic Juvenile Arthritis Treatment market in the near future?4. What are the current trends and key developments that are expected to impact the market significantly by the end of 2025?5. What is the landscape of the competitive scenario of the global Systemic Idiopathic Juvenile Arthritis Treatment market?6. What are the most commonly adopted growth strategies adopted by the dominating players in the Systemic Idiopathic Juvenile Arthritis Treatment market?

Grab Your Report at an Impressive Discount! Please click Here @ https://www.marketgrowthinsight.com/discount/16866

Table of Contents:

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Systemic Idiopathic Juvenile Arthritis Treatment market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Systemic Idiopathic Juvenile Arthritis Treatment market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the global Systemic Idiopathic Juvenile Arthritis Treatment market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Systemic Idiopathic Juvenile Arthritis Treatment market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Systemic Idiopathic Juvenile Arthritis Treatment market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Systemic Idiopathic Juvenile Arthritis Treatment market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behaviour and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Systemic Idiopathic Juvenile Arthritis Treatment market.

Make an Enquiry for purchasing this Report @ https://www.marketgrowthinsight.com/inquiry/16866

About Market Growth Insight

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas. The skilled and experienced professionals at Market Growth Insight are our strength and the position we have earned in the industry. This is what makes us to offer our clients to excel and enable competitive prices while retaining the best services. We are incorporated with a vision to provide the complete solution required for successful business execution. Our only motto is to resolve customer fulfillment completely. We provide the quality and customized research reports from the best publishers in the world.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

Read more:
Get In Depth Analysis Of How Covid-19 Is Impacting The Systemic Idiopathic Juvenile Arthritis Treatment Market - The Think Curiouser

The Rheumatoid Arthritis Diagnosis Tests market report is an ultimate solution for businesses if they want to stay ahead of the competition in todays fast moving business environment.

What is more, business can also have details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry in this Rheumatoid Arthritis Diagnosis Tests market analysis report.

This Rheumatoid Arthritis Diagnosis Tests market report is mainly delivered to the users in the form of PDF or spreadsheet. However, PPT format can also be offered if the client has specified such requirement.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2814797&source=atm

Rheumatoid Arthritis Diagnosis Tests Market Characterization-:

The overall Rheumatoid Arthritis Diagnosis Tests market is characterized on the basis of different analysis-:

Rheumatoid Arthritis Diagnosis Tests market is expected to grow at a rate of X.XX% in the forecast period 2020 to 2027.

Global Rheumatoid Arthritis Diagnosis Tests Market Scope and Market Size

Global Rheumatoid Arthritis Diagnosis Tests market is segmented on the basis of type and application. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of type, Rheumatoid Arthritis Diagnosis Tests market is segmented into platform as a service and application program interface.

The application segment of the Rheumatoid Arthritis Diagnosis Tests market is divided into personal use, large enterprise, small medium enterprise (SMEs), and other

Rheumatoid Arthritis Diagnosis Tests Market Country Level Analysis

Global Rheumatoid Arthritis Diagnosis Tests market is analysed and market size, volume information is provided by type and application as referenced above.

Key Rheumatoid Arthritis Diagnosis Tests market players Analysis-:

The study given in this section offers details of key market players. It likewise clarifies the marketing strategies adopted by these players as well as portrays their shareholdings in the Rheumatoid Arthritis Diagnosis Tests market.

segment by Type, the product can be split intoSerology TestsMonitoring RA Treatment Efficiency Tests

Market segment by Application, split intoDiagnostic LaboratoriesAmbulatory Surgical CentersHospitals

Based on regional and country-level analysis, the Rheumatoid Arthritis Diagnosis Tests market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Rheumatoid Arthritis Diagnosis Tests market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyAbbottBeckman CoulterEuro DiagnosticaRocheQiagenSiemens HealthcareThermo Fisher ScientificBio Rad LaboratoriesAviva Systems Biology

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2814797&source=atm

Regional Segments Analysis:

The Middle East and Africa (GCC Countries and Egypt.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia.)

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2814797&licType=S&source=atm

Set of Chapter covered in this report-:

Part 01: Rheumatoid Arthritis Diagnosis Tests Market Overview

Part 02: Manufacturers Profiles

Part 03: Global Rheumatoid Arthritis Diagnosis Tests Market Competition, by Players

Part 04: Global Rheumatoid Arthritis Diagnosis Tests Market Size by Regions

Part 05: North America Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 06: Europe Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 07: Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 08: South America Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 09: Middle East and Africa Revenue Rheumatoid Arthritis Diagnosis Tests by Countries

.so on

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

View post:
Global Rheumatoid Arthritis Diagnosis Tests Market : Current Trends and Future Estimations to Elucidate Imminent Investment Pockets - The Think...

The global canine arthritis treatment market is expected to rise with an impressive CAGR and generate the highest revenue by 2026.Fortune Business Insights in its latest report published this information. The report is titled Canine Arthritis Treatment Market Size, Share and Global Trend By Product (Surgical Procedures, Medications, Nutritional Therapy, Others), and Geography Forecast till 2026. The report discusses research objectives, research scope, methodology, timeline and challenges during the entire forecast period. It also offers an exclusive insight into various details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies.

For more information, Get sample pdf @https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/canine-arthritis-treatment-market-100675

The report provides a 360-degree overview of the market, listing various factors restricting, propelling, and obstructing the market in the forecast duration. The report also provides additional information such as interesting insights, key industry developments, detailed segmentation of the market, list of prominent players operating in the market, and other canine arthritis treatment market trends. The report is available for sale on the company website.

some of the key players in the global Canine Arthritis Treatmentmarket:

North America to dominate the global market

Geographically, the global canine arthritis treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is presently leading the global canine arthritis treatment market. The region is predicted to dominate the global canine arthritis treatment market during the forecast period, owing to the rising prevalence of canine arthritis and growing ownership of pet dogs. According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017. The Asia-pacific followed by Middle East & Africa are predicted to grow significantly during the forecast period due to increasing ownership of dogs and increasing awareness of canine arthritis in the region. In addition, developing veterinary healthcare infrastructure in emerging countries such as China and India are anticipated to fuel demand for canine arthritis treatment and hence fostering the growth of global canine arthritis treatment market during the forecast period

View press release for more information @https://www.fortunebusinessinsights.com/industry-reports/canine-arthritis-treatment-market-100675

Regional Analysis for Canine Arthritis Treatment Market:

Major Table of Contents for Canine Arthritis Treatment Market:

Other Exclusive Reports:

Drug Eluting Stent Market

Urinalysis Market

Disposable Respirators Market

Patient Engagement Solutions Market

SUBSTANCE ABUSE TREATMENT Market

Syphilis Rapid Test Kits Market

Muscarinic Acetylcholine Receptor Market

About Us:Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact:Name: Ashwin AroraEmail:[emailprotected]Phone: US +1 424 253 0390 / UK +44 2071 939123 / APAC: +91 744 740 1245

View original post here:
Canine Arthritis Treatment Market 2020 | Global Trends, Covid-19 Impact, Share, Insights, Growth, and Outlook upto 2026 - Aerospace Journal

Treatment with otilimab, a monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), is well tolerated, despite optimal exposure, and may improve synovitis in patients with active rheumatoid arthritis (RA), according to study results published in Lancet Rheumatology.

Previous studies have reported that GM-CSF can act as a proinflammatory cytokine and has an important role in a broad range of immune-mediated conditions, making it a valuable therapeutic target in patients with RA. The objective of the current mechanistic phase 2a study was to determine the effect of otilimab on the GM-CSF-chemokine (C-C motif) ligand 17 (CCL17) axis and synovitis in patients with RA.

The multicenter, randomized, placebo-controlled study (ClinicalTrials.gov Identifier: NCT02799472) included adult patients with RA from across 9 sites in the United States, Poland, and Germany. Participants were randomly assigned to receive either 180 mg of subcutaneous otilimab or placebo. The primary outcome was change over time in 112 biomarkers. Secondary end points included change from baseline in synovitis, osteitis, and erosion assessed by the RA magnetic resonance imaging (MRI) Scoring (RAMRIS) system, RA MRI Quantitative (RAMRIQ) score, and safety evaluation.

A total of 39 patients with RA who were randomly assigned to receive otilimab (n=28) or placebo (n=11) were included in the final cohort. Weekly subcutaneous injections of otilimab 180 mg or placebo were administered for 5 weeks, then every other week until week 10, followed by a 12-week safety follow-up.

Results showed that mean serum concentrations of the GM-CSF-otilimab complex peaked at week 4 (138.4 ng/L), but reduced from week 6 to 12, with CCL17 concentrations decreasing and then returning to baseline at week 12 (least-squares mean ratios at weeks 2, 4, 6, and 8 were 0.65, 0.68, 0.78, and 0.68, respectively). In the placebo group, no significant changes in CCL17 concentrations were noted. There were also no differences between groups for all other biomarkers.

Results from imaging measures of synovitis showed a reduction from baseline to week 12 in patients who received otilimab. Differences in MRI outcomes were minimal, and a trend for reduced synovitis and osteitis was seen early during active treatment, but not at 12 weeks after the treatment was stopped. The RAMRIS synovitis score showed a least-squares mean change from baseline of -1.3 (SE, 0.6) in the otilimab group and a mean change of 0.8 (SE, 1.2) in the placebo group (P =.11). The RAMRIQ synovitis score showed a least-squares mean change from baseline of -1417.0 L in the otilimab group and -912.3 L with placebo (P =.75).

All adverse events were reported to be mild or moderate, and the number of adverse events was similar in the otilimab and placebo groups (39% and 36%, respectively). The most common adverse event was cough (7%) in the active treatment group and pain in extremity (18%) and RA (18%) in the placebo group. There were no serious adverse events or deaths.

The study had several limitations, including the relatively small sample size, imbalanced baseline disease-modifying antirheumatic drug use among treatment groups, and the determination of the RAMRIS synovitis score based on assessment by a single radiologist.

The findings of this study support the rationale for the further clinical development of otilimab as a treatment option for patients with [RA]. Additionally, the effect of otilimab on CCL17 indicates that CCL17 shows promise as a pharmacodynamic biomarker for otilimab in future studies, the researchers concluded.

Disclosure: This clinical trial was supported by GlaxoSmithKline. Please see the original reference for a full list of authors disclosures.

Genovese MC, Berkowitz M, Conaghan PG, et al. MRI of the joint and evaluation of the granulocytemacrophage colony-stimulating factorCCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatol. Published online October 7, 2020. doi:10.1016/s2665-9913(20)30224-1

Excerpt from:
Otilimab Well Tolerated and May Improve Synovitis in Active Rheumatoid Arthritis - Rheumatology Advisor

Background:Rheumatoid arthritis (RA) is a rheumatic disease characterized by erosive synovitis and polyarthritis. Exercise is known to improve many symptoms in RA patients.

Aim:This study was designed to compare the effects of pilates exercises, aerobic exercises, and combined training including pilates with aerobic exercises on fatigue, depression, aerobic capacity, pain, sleep quality, and quality of life.

Methods:Thirty voluntary RA patients were included in this study. Patients were divided into three groups equally, and treatment was applied to each group for 8 weeks. Pilates exercises were practiced to the first group, aerobic exercises were practiced to the second group, and combined training was performed to the third group. Fatigue, depression, aerobic capacity, pain, sleep quality, and quality of life were evaluated using Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), 6-minute walk test (6MWT), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburg Sleep Quality Index (PSQI), and Rheumatoid Arthritis Quality of Life (RAQoL), respectively.

Results:The results of the present study showed significant improvements for the first group on fatigue, depression, aerobic capacity, and quality of life (p < 0.05). Improvements in all parameters except for pain were obtained for the second and third groups (p < 0.05). In addition, there was no statistically significant difference among the treatment groups in assessments (p > 0.05).

Conclusion:Pilates exercises may have similar effects to aerobic exercises in patients with RA. Addition of clinical pilates exercises to the routine treatment of RA may enhance the success of rehabilitation. Trial registrationNCT03836820.

Keywords:Aerobic exercises; Fatigue; Pilates exercises; Rheumatoid arthritis.

Link:
Comparison of the effectiveness of pilates exercises, aerobic exercises, and pilates with aerobic exercises in patients with rheumatoid arthritis -...

TRUMBULL, Conn., Oct. 22, 2020 /PRNewswire/ --ZetrOZ Systems, developers of sustained acoustic medicine (SAM), an FDA-cleared home-use ultrasound device that helps reduce pain associated with tendon, ligament, and muscle injuries, has received funding from the National Institute of Health (NIH) to find a way to reduce arthritic pain utilizing non-surgical, non-narcotic technology.

Arthritic pain has been primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), namely diclofenac. Diclofenac, which is administered topically, is limited in its efficacy due to its limited ability to penetrate the skin. New findings from researchers at the University of Cincinnati show SAM technology's ability to deliver NSAIDs locally and effectively, demonstrating 380% enhanced delivery compared to existing technology for the treatment of joint pain.

"Targeted and localized drug delivery is the holy grail for many therapeutic agents, and this has been demonstrated with small-molecule therapeutics, combined with our latest sam 2.0," says Dr. George Lewis, CEO of ZetrOZ Systems. "The research community is excited by the findings, as it has broad implications for the local delivery of therapeutic agents without the need for oral delivery."

The study published in the Journal of Therapeutic Delivery Vol 11. NO 6.investigated the use of sam 2.0, "a multi-hour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin." The use of sam 2.0 medical technology resulted in increased delivery of diclofenac by 380% and increased depth of penetration of the skin by 32%. Findings concluded that sustained acoustic medicine can be used as an effective transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs.

"Our collaborations with the top research institutions such as the University of Cincinnati foster continuous innovation on sustained acoustic medicine in the treatment of chronic pain," adds Lewis.

About ZetrOZ Systems

ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more at zetroz.comand samrecover.com.

Media Contact: [emailprotected]

Related Images

sam-2-0-medical-technology.jpg SAM 2.0 medical technology featured in the Journal of Therapeutic Delivery for the treatment of chronic arthritis pain

SOURCE ZetrOZ Systems

See the rest here:
ZetrOZ Receives Funding from the National Institute of Health to Find New Ways to Reduce Arthritic Pain for Over 60 Million Americans Using...

CHANDAN KHANNA/AFP/Getty Images A medic prepares to transfer a patient on a stretcher from an ambulance outside of Emergency at Coral Gables Hospital where Coronavirus patients are treated in Coral Gables near Miami, on July 30, 2020. - Florida has emerged as a major new epicenter of the US battle against the disease, with confirmed cases recently surpassing New York and now second only to California. The state toll has leapt over the past week and more than 6,500 people have died from the disease there, according to health officials. More than 460,000 people have been infected with the virus in Florida, which has a population of 21 million, and a quarter of the state's cases are in Miami. The US has tallied a total of 151,826 deaths from COVID-19, making it the hardest-hit country in the world. (Photo by CHANDAN KHANNA / AFP) (Photo by CHANDAN KHANNA/AFP via Getty Images)

Tocilizumab, a repurposed rheumatoid arthritis drug once considered a promising treatment for hospitalized patients with Covid-19, generally did not increase patients' chances of survival or help them get better faster, according to three trials published this week.

However, a fourth trial did find the drug increased the chances of survival, but because it was an observational study, the results are considered less definitive.

Three of the trials were published Tuesday in the Journal of the American Medical Association and the other was published Wednesday in the New England Journal of Medicine.

While this leaves the picture for tocilizumab use a bit muddy, the studies taken together show the drug isn't a magic bullet that should be used in all hospitalized patients with Covid-19, but they leave the door open for possible use in specific patient groups.

"It is possible that forthcoming results from other randomized trials will help us identify specific groups of people who will benefit. However, growing evidence supports current guidelines, which recommend against tocilizumab use outside of clinical trials," Dr. Jonathan Parr told CNN.

Parr, an assistant professor in the division of infectious diseases at the University of North Carolina at Chapel Hill, wrote an editorial that was published alongside the three studies in JAMA.

Tocilizumab, sold under the brand name Actemra and used to treat rheumatoid arthritis, blocks interleukin-6, a molecule that produces inflammation.

Earlier in the pandemic, the drug became widely used in the United States after reports from China and Europe appeared to show it helped very ill patients who experienced a so-called cytokine storm by extinguishing the out-of-control inflammation that developed in response to the coronavirus.

However, those early reports were mostly observational, meaning they took existing data and analyzed it as opposed to designing a trial specifically to assess tocilizumab.

But now the results from trials designed to look at the drug prospectively are beginning to come in.

The first of the three JAMA studies found that hospitalized patients in Italy who were not yet in intensive care and who received tocilizumab fared no better than those who received standard care. The trial was stopped early due to "futility."

A similar study in France found that tocilizumab may have led to slight improvements by day 14 over usual care, but there were no differences in survival by day 28.

The third study found that the risk of in-hospital death was about 30% lower in US patients receiving tocilizumab within the first two days of ICU admission compared to those who didn't get the drug.

But because it was an observational trial there could be factors that affected the results other than how well the drug itself worked.

"We specifically studied tocilizumab administration in very sick patients, all of whom required ICU level of care. In contrast, the [other two trials] studied patients with much milder illness severity," said Dr. Shruti Gupta of Brigham and Women's Hospital in Boston, who led the study team.

Dr. David Leaf, the trial's senior author, added, "We focused on early use of tocilizumab -- within the first two days of ICU admission. This may be the key to tocilizumab's efficacy -- administering it prior to the occurrence of irreversible organ injury," he said in an email.

Gupta said their findings need confirmation by a large randomized, controlled trial.

The fourth study, published Wednesday in the New England Journal of Medicine, used the gold standard of trial design-- it's a randomized, double-blind, placebo control trial.

It enrolled 243 patients from seven Boston-area hospitals who were admitted with Covid-19 at the height of the surge in that region.

"The primary goal of the trial was to determine if tocilizumab, administered intravenously at a moderate stage of the patients' disease, could prevent progression to intubation or death," said Dr. John H. Stone, lead study author and director of Clinical Rheumatology at Massachusetts General Hospital, told CNN via email.

But the findings were not encouraging for the use of tocilizumab.

"Our data do not support the concept that early IL-6 receptor blockade is an effective treatment strategy in moderately ill patients hospitalized with Covid-19 infection," said Stone.

Results show that the chances of intubation or death were about similar in both groups and patients in both groups essentially took the same amount of time to discontinue supplemental oxygen.

So, where does that leave tocilizumab?

"Tocilizumab may still have a role in COVID-19. Several large trials are expected to come out soon that will tell us more about how and when it should be used, if at all," said Parr, noting that it "shouldn't be taken off the table completely, but we need more convincing evidence before using it routinely."

Stone agreed that the drug may still benefit other patient groups, but he stressed the importance of doing these trials.

"An important take-away point from our trial and the overall experience with IL-6 receptor blockade is that any such approach to the treatment of COVID-19 must be subjected to randomized, blinded trials," he said, adding that the trials should be done "before the adoption of widespread use."

View original post here:
Rheumatoid arthritis drug tocilizumab falls short as treatment for hospitalized Covid-19 patients in three studies - msnNOW

New Study Reports Rheumatoid Arthritis Stem Cell Therapy Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026 has been Added on Fact.MR.OverviewStarting from the fundamental details, the report provides a complete overview of the industry along with a proper market profile. The details provided here about the crucial technologies used for manufacturing and product management purpose makes it easier to have a thorough insight into the Global Rheumatoid Arthritis Stem Cell Therapy Market. Based on the information obtained, the market has been segmented into various categories. It predicts the growth rate of the Global Rheumatoid Arthritis Stem Cell Therapy Market in between the forecasted period, having a base year as 2020.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

This report focuses Global Rheumatoid Arthritis Stem Cell Therapy market, it covers details as following:Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Market DynamicsThe report identifies all the key aspects that drive the super-fast growth of the international Global Rheumatoid Arthritis Stem Cell Therapy Market. In this context, it identifies the crucial aspects regarding the pricing part of the concerned product. It analyses the market value of each of the products and services as well in the report, including the various kinds of volume trends. Prime aspects that are covered in this report range from the effect of growing population at international level, accelerating technological growth, and the analysis of level of demand and supply as evident in the Global Rheumatoid Arthritis Stem Cell Therapy Market. The report also covers extensive studies regarding various effects in relation to the initiatives taken by the government and the competitive platform that is there in the Global Rheumatoid Arthritis Stem Cell Therapy Market in between the forecasted period. Segmental AnalysisThe report does thorough segmentation of international Global Rheumatoid Arthritis Stem Cell Therapy Market upon taking various factors associated with the growth of the market. It does a thorough regional segmentation. These segmentation based studies are done with an intention of achieving a thorough and specific insight of the Global Rheumatoid Arthritis Stem Cell Therapy Market. The report does a regional analysis of the key zones of the world, starting from the US, North America, Latin America, Middle East & Africa, and Asia. Modes of researchThe research being done by experienced experts has done a comprehensive analysis of Global Rheumatoid Arthritis Stem Cell Therapy Market based on Porters Five Force Model, taking the assessment period between 2020-2026 into account. Additionally, a deep SWOT analysis is done to facilitate quick decision making for the associated people in the Global Rheumatoid Arthritis Stem Cell Therapy Market.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Report covers:Comprehensive research methodology of Global Rheumatoid Arthritis Stem Cell Therapy Market.This report also includes detailed and extensive market overview with gap analysis, historical analysis & key analyst insights.An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.Analysis of regional regulations and other government policies impacting the Global Rheumatoid Arthritis Stem Cell Therapy Market.Insights about market determinants which are stimulating the Global Rheumatoid Arthritis Stem Cell Therapy Market.Detailed and extensive market segments with regional distribution of forecasted revenuesExtensive profiles and recent developments of market players

Read more from the original source:
Rheumatoid Arthritis Stem Cell Therapy Market Highlights On Future Development 2018 to 2028 - TechnoWeekly

Objective:To ascertain the role of platelet glycoprotein Ib alpha chain (GPIb) plasma protein levels in cardiovascular, autoimmune and autoinflammatory diseases and whether its effects are mediated by platelet count.

Methods:We performed a two-sample Mendelian randomization (MR) study, using both cis and trans-acting protein expression quantitative trait loci (pQTL) near GP1BA and BRAP genes as instruments. To assess if platelet count mediated the effect, we then performed a two-step MR study. Putative associations (GPIb/ platelet count/ disease) detected by MR analyses were subsequently assessed using multiple-trait-colocalization analyses.

Results:After correcting for multiple testing (P 210-3), GPIb, instrumented by either cis-pQTL or trans-pQTL, was causally implicated with increased risk of juvenile idiopathic arthritis (JIA oligoarticular and rheumatoid factor negative subtypes). These effects of GPIb appear to be mediated by platelet count and are supported by strong evidence of colocalization (probability of all three traits sharing a common causal variant 0.80). GPIb instrumented by cis-pQTL did not appear to affect cardiovascular risk, although the GPIb trans-pQTL associates with increased risk of cardiovascular diseases and autoimmune diseases but decreased risk of autoinflammatory diseases, suggesting this trans- instrument acts through other pathways.

Conclusion:The role of platelets in thrombosis is well-established, however our findings provided some novel genetic evidence that platelets may be causally implicated in the development of JIA, and GPIba as a putative therapeutic target for these JIA subtypes.

Visit link:
Platelet glycoprotein Ib alpha chain as a putative therapeutic target for juvenile idiopathic arthritis: a Mendelian randomization study - DocWire...

Arthritis affects over 350 million people in the world.

It is also a leading cause of disability and can affect mobility and interrupt peoples ability to perform simple daily tasks.

World Arthritis Day was on October 12, which aimed to raise awareness about rheumatic and musculoskeletal diseases. Although strides have been made to find suitable treatments, many continue to suffer from debilitating pain.

Owner and founder of The Harvest Table, Catherine Clark, said there are natural remedies which can help manage symptoms associated with arthritis.

There is no cure for arthritis, but if you support your body with the right foods and supplements, you can alleviate some of the pain so that it doesnt become a hindrance in your daily life, said Clark.

Clark added that arthritis can affect ones energy levels, cause pain, and is a direct result of a loss of collagen in the bones.

ALSO READ:

Affinity Health shares how smoking may affect your surgery

The key is to find solutions that will help you feel less fatigued, while also managing pain and replenishing the collagen lost, she said. Clark offers three natural remedies to manage arthritis pain:

Anti-inflammatory foodsArthritis fatigue is real, and according to the Arthritis Foundation, unchecked inflammation and pain largely contribute to your energy levels, along with certain medications that can cause drowsiness.Boosting your energy starts with nourishing your body with the right foods, especially those with high anti-inflammatory properties that help your bodies repair process. This will not only alleviate pain but will reduce the inflammation in your body. To effectively manage your arthritis, reduce the amounts of processed foods and saturated fats as these will only further contribute to your symptoms. Instead, choose fresh fruits and vegetables, especially green vegetables and berries. Also include fish and nuts, which both contain high anti-inflammatory properties.

Slow and gentle movementMovement is a critical part of recovery when addressing the symptoms of arthritis as it retains the suppleness of your joints. Various low impact movements can specifically tackle flexibility, strength and generally support your joints to prevent injury. Prolonged lack of movement can lead to chronic stiffness that results into joint immobility which will impact your ability to complete daily activities. Yoga is an effective solution as it reduces joint pain and also eases stress, tension and promotes better quality sleep.

Collagen-rich supplementsCollagen consists of protein building blocks, otherwise known as amino acids, which aid in cushioning our joints. When you have arthritis, this cushioning diminishes which then affects your cartilage and leads to your bones rubbing against each other without protection. Supplements like Bone Broth and Collagen granules help replenish the collagen content in your body. Bone Broth is a natural anti-inflammatory, so when you have it as part of your diet, you benefit in more ways than one. Collagen granules can help reduce both osteoarthritis and rheumatoid arthritis joint pain, improve flexibility, and helps form new bones. Although all the collagen you ingest does not go straight to your bones, increasing your intake makes them readily available for your body tissues.

Natural remedies are meant to support your body so that you can better manage pain and other symptoms associated with arthritis.

The idea is to implement small and manageable changes that contribute to you feeling better and having the energy and ability to get through the day without pain getting in the way, Clark concludes.

Have a story?

Contact the newsroom by emailing:Editor at[emailprotected],or Busi Vilakazi (Journalist)[emailprotected]Also follow us on:

Read this article:
Try these three natural remedies to manage arthritis pain - Germiston City News

The report on Septic Arthritis Treatment Marketgives an analysis of Septic Arthritis Treatment Industry dependent on angles that are significant for the market study. Factors like production, the share of the overall industry, revenue rate, regions and key players characterize an overall market study. This report gives an overview of market esteemed and its development in the coming years. It likewise predicts CAGR.

Get Free Sample on this Premium Septic Arthritis Treatment Market Research Report- https://www.affluencemarketreports.com/industry-analysis/request-sample/634631/

The report is a thorough examination of this market over the world. It offers an outline of the market including its definition, applications, key drivers, key market players, key segments, and assembling innovation. Furthermore, the research report presents factual information on the status of the market and subsequently is an important wellspring of direction for companies and individuals interested in the businesses. Also, in-depth knowledge on the company profiles, product particulars, capacity, production worth, and market shares of key players are introduced in the report.

Major Key Players in this Septic Arthritis Treatment Market Report are as follows:

Lupin Pharmaceuticals (US), F. Hoffmann-La Roche Ltd (Swtizerland), AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US) , Johnson & Johnson (US), Pfizer (US) ,

The Report is Segmented as Following:

With an overall methodology for information aggregation, the market situations include significant players, cost and pricing working in particular geographies. Statistical looking over-utilized are SWOT Analysis, PESTLE analysis, prescient examination, and constant examination. Charts are plainly used to help the data format for a clear understanding of facts and figures.

Get COVID-19 Impact Analysis on this Premium Septic Arthritis Treatment Market Reports- https://www.affluencemarketreports.com/industry-analysis/covid19-request/634631/

The report further explains on the restraining elements in the Septic Arthritis Treatment market for individuals, strategists, and partners to deliberately execute their techniques and accomplish their objectives. Whats more, the Septic Arthritis Treatment market is segmented based on product, innovation, and end-user. This Septic Arthritis Treatment Research report segments are altogether concentrated to offer key data like open doors for business owners, planners, and marketing staff. It encourages them to deal with their activities and execute unequivocal to earn more profits. Septic Arthritis Treatment Report offers insights on each segment and sub-segment for assisting producers to identify key opportunities and grow their business.

Report Highlights

If you have any Query on this research report ask our experts- https://www.affluencemarketreports.com/industry-analysis/request-inquiry/634631/

About Us:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone: (US) +1-(424) 256-1722

[emailprotected]

Website: http://www.affluencemarketreports.com

Original post:
Septic Arthritis Treatment Market 2020| Know The Latest Trends, Business Outlook, New Opportunities By Top Key Player | Affluence Market Reports -...

When it comes to exercise for arthritis, even simple moves like stretching can help ease joint pain and stiffness.

Image Credit: kali9/E+/GettyImages

If you have arthritis, going for a jog may seem like it would do your joints more harm than good. But as counterintuitive as it seems, physical activity may be just what the doctor ordered.

About 54 million people in the U.S. have been diagnosed with arthritis, an inflammatory condition that causes joint pain and swelling.

These symptoms can also prevent people from exercising: Almost 24 percent of people with arthritis don't do any physical activity (compared to about 18 percent of those without the condition), according to the Centers for Disease Control and Prevention (CDC).

"In general, people with arthritis tend to want to take it easy or not exercise as much," Brian Andonian, MD, a rheumatologist and assistant professor of medicine at Duke University School of Medicine, tells LIVESTRONG.com. "But exercise, done right, is probably one of the most beneficial things they can do to help their joints."

Osteoarthritis, the most common type of arthritis in the U.S., occurs when the cartilage surrounding the ends of bones (such as those of the knees and hands) break down which is partly why it's known as "wear and tear" arthritis. But in some ways, that definition can be misleading.

"The 'wear and tear' component is really much more specific," says Joseph Garry, MD, a visiting professor of clinical family medicine at the University of Illinois College of Medicine Rockford. "It's not so much moving or exercising."

Rather, he explains, osteoarthritis can be caused by overloading the joint, by being overweight, maybe, or by carrying lots of heavy objects at work. Joint injuries, such as those sustained by playing a sport, may also increase the risk for osteoarthritis, he says.

Exercise, however, can help ease pain from osteoarthritis as well as from other inflammatory types of arthritis, including rheumatoid and psoriatic arthritis, says Dr. Andonian.

Ready to get started? Here's a closer look at why exercise is so beneficial for people with arthritis, and how to start working out safely.

Why Exercise Is Good for Arthritis

Exercise can reduce pain, improve joint function and boost the quality of life of people with arthritis, according to the CDC.

One early investigation into exercise and arthritis, published January 2008 in the journal Arthritis & Rheumatism, found that people with arthritis who participated in an exercise program felt less pain and fatigue at the end of eight weeks than those who didn't work out. Plus, they continued to feel less pain and fatigue six months later.

Newer research has confirmed those findings, concluding that even short periods of activity can help prevent joint pain from worsening. In a study published May 2019 in the American Journal of Preventive Medicine, people with joint pain who performed one hour of moderate-to-vigorous activity a week were less likely to develop a disability after four years as those who weren't as active.

"Any exercise for somebody with arthritis who's sedentary is going to be helpful. Every little bit adds up, even a few minutes here and there."

Exercise can help ease joint pain in a few ways, says Dr. Andonian. For starters, he says, physical activity can strengthen the muscles that surround the joint, which helps take some of the pressure off the joint itself. It also helps you sleep better, which can also help ease pain.

Another way exercise can help ease arthritis symptoms is by lowering the levels of inflammation in the body, which is a characteristic of arthritis, he says.

"I think of exercise as being an anti-inflammatory treatment," says Dr. Andonian. "We know that exercise has pretty powerful ways of [regulating] the way the immune system works."

Specifically, he explains, fat is more pro-inflammatory than lean muscle mass, which tends to be more anti-inflammatory and beneficial for arthritis.

The Best Types of Exercise for Arthritis

Yoga is a great way to improve your balance and range of motion when you have arthritis.

Image Credit: Ridofranz/iStock/GettyImages

Because both aerobic exercise and strength training improve body composition, doing either one and ideally both can help improve arthritis symptoms, Dr. Andonian says.

Other types of activity that you may want to try include range-of-motion and body awareness exercises, according to the American College of Rheumatology.

Here are some examples of these four main types of exercise, plus good options for people with arthritis:

3. Range-of-Motion Exercises

4. Body Awareness Workouts

If you're just starting an exercise program, one of the best things you can do is commit to an activity that you like to do, and one that's also compatible with your schedule and lifestyle.

"Keeping up a program in the long-term has got to be enjoyable," Dr. Andonian says.

The CDC recommends adults get at least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous exercise each week, but if you haven't been exercising very much (if at all), try working up to that goal slowly, over time, says Dr. Andonian.

"Any exercise for somebody with arthritis who's sedentary is going to be helpful," he says. "Every little bit adds up, even a few minutes here and there."

Are There Any Risks to Exercising With Arthritis?

Before you start a new exercise program, it's a good idea to let your doctor know what you're doing, says Dr. Andonian. Your provider may be able to refer you to another health care professional, like a physical therapist, who can design a workout plan for you and even help coach you through the movements.

After you start exercising, you'll probably feel some stiffness or swelling, possibly for six to eight weeks, according to the CDC. But that's OK.

"A little bit of soreness isn't necessarily a bad thing, especially if you're starting to get some gains over time," Dr. Andonian says.

That said, you may want to modify certain exercises to make them more comfortable for you, he says. For example, if you have knee osteoarthritis, you can try starting a walking program, but avoid climbing a lot of hills. Or, if you want to try cycling but have arthritis in your spine or hip, he recommends sitting on a bike in a reclined position, which can be more comfortable.

Even if you're having a flare-up of arthritis, it's still a good idea to try to do some exercise.

"A lot of people just completely stop all activities," he says. "I recommend that people try to stay active as much as they can within their comfort zone, even just doing light activities like range-of-motion type exercises."

If you happen to feel any sharp, stabbing and constant pain, pain that causes you to limp or pain in your joints that are red or feel "hot," the CDC recommends calling your doctor.

Read the original:
The 4 Best Types of Exercise to Ease Arthritis Pain and Stiffness - LIVESTRONG.COM

Arthritis leads to inflammation and pain in joints. It reduces mobility and make it difficult to perform day to day activities. Here are some foods that you should avoid if suffering from arthritis.

Arthritis diet should include foods anti-inflammatory foods

Arthritis is a condition that affects the joints of an individual. It leads to pain, stiffness and inflammation in the joints. The symptoms of arthritis worsen with age. There are several types of arthritis that can affect a person. Pain, stiffness, swelling, reduced range of motion and redness near the joints are some typical symptoms of this condition. Arthritis diet includes foods that can help ease inflammation and joint pain. It is usually suggested to add anti-inflammatory foods to an arthritis diet. Therefore, people with arthritis are often advised to avoid foods that can trigger inflammation. Here's a list of foods that people with arthritis should be avoiding.

Consumption of sugar in excess can result in inflammation as per studies. It can also lead to weight gain which can make it hard to manage this condition. Sugar is usually hidden in several foods and drinks. You should also avoid foods with added sugar.

Consuming too much sugar can contribute to weight gainPhoto Credit: iStock

Ultra-processed foods may also contain inflammatory ingredients that can worsen the symptoms of arthritis. Highly processed foods are generally high in salt and sugar which are harmful to your health when consumed in excess.

Also read:Arthritis Diet: 5 Anti-Inflammatory Foods That Should Be A Part Of Your Diet

Studies have shown that drinking too much alcohol can increase the severity of gout which is a type of arthritis. It can also increase inflammation. Too much alcohol consumption is also linked with several health conditions.

Also read:These Remedies Can Help Relieve Arthritis Pain Naturally

Promoted

Studies have also highlighted that consuming processed meat regularly may demonstrate high levels of inflammation.

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

View post:
Arthritis Diet: Avoid These Foods And Drinks To Fight Inflammation Effectively - Doctor NDTV

Working in the medical field for over 30 years helped me navigate health care appointments for my rheumatoid arthritis. I'm not afraid to ask if I need a test, and if I think that something needs to be looked at, I'm not shy: I ask. The patient has a right to do that, and I have a very good relationship with my health care team.

After years of trying different medications that I couldnt tolerate for long periods or that didn't work for me, including methotrexate and NSAIDs, I started taking a biologic in 2001, 10 years after my diagnosis. Im still on it. For me, its been a life changer. I think its the reason Im still able to work full-time, which in turn keeps me going.

What also helped was finding a community who understood what I was going through. In 1991, the only way I could see how people handled living with rheumatoid arthritis was by watching VHS tapes from the library. I didnt know anyone else with arthritis when I was diagnosed, or anyone else on my treatment. I wanted to talk to somebody else and see how it was going for them, and share my great experience with people.

For years, it felt like no one understood. If I tried to talk to someone about the pain and the obstacles I was facing, people accused me of being negative. I needed to find people who were uplifting.

In 2002, I discovered CreakyJoints, a community for people with arthritis. Meeting other people online in the chat room and later on the Facebook page was really helpful, and I started reading the monthly newsletter. Although Im naturally a shy person, I wanted to get more involved. I edited the poetry section of the newsletter for three years, helped put together a book in 2017, and became one of the first members of the patients council. We meet monthly and work on pamphlets to help raise awareness, especially about the mental health side of living with arthritis. I really want people to know that if you're having a hard time coping, it's okay to find somebody to talk to. You don't have to go this alone. There are people out there just like you. And when you reach out for help, youre not only helping yourself, youre helping others as well.

As hard as rheumatoid arthritis can be, Ive always had hope. In 2020, I started noticing that I was feeling better. Things like getting dressed, which could be absolute agony, were easier. I started seeing a new rheumatologist in February, and after a check-up in August, I found out I was already in remission. I thought, I'm in remission? I was shockedit was awesome!

Being in remission from rheumatoid arthritis is almost like being given a gift. I was briefly in remission 10 years ago, and even though it only lasted a couple of months, I always said it could happen again: I never gave up hope. Im hoping it will last longer this time.

Im very aware that I still live with rheumatoid arthritis. It hasn't suddenly gone away, it's just that things are quiet right now. I still experience fatigue and I still live with pain. I have joint deformity from before I started taking the treatment Im on, and that will never be fixed. But I havent had very bad days since remission. I still have to be vigilant and keep taking my medication, and keep doing all the things Ive been doing to stay healthy. Exercise is very important; I walk half a mile to and from work most weekdays, even in the winter! I also know when to rest, especially since Im more vulnerable to infections on the medication.

Attitude is so important too. When you have rheumatoid arthritis, not every day is going to be great. But I find that if you can bring humor, even when you're in pain, it can at least get your mind off it for a little while. And dont ever give up hope. I trust scientists, and just look at the drugs that are out there now, and the ones that are still being developed. Ive lived with the disease for a long time, and I want people to know that Im proof that remission can happenand its great.

This interview has been edited and condensed for clarity.

Related:

View post:
Rheumatoid Arthritis Remission: This Is What It Really Feels Like - Self